Autologous tumor lysate/Bacillus Calmette–Guérin immunotherapy as an adjuvant to conventional breast cancer therapy

Clinical and Translational Oncology

Volumn 17, Issue 11, 2015, Pages 884-887

  Convit, J ^a   Montesinos, H ^b   Oviedo, H ^a   Romero, G ^c   Maccarone, B ^d   Essenfeld, E ^d   Convit, A ^e   Palacios, L E ^c  

^a Instituto de Biomedicina Dr Jacinto Convit   (Venezuela)

^b UNIVERSIDAD SIMÓN BOLÍVAR   (Venezuela)

^c Hospital Oncológico Dr Luis Razetti   (Venezuela)

^d Policlinica Metropolitana   (Venezuela)

^e Unidad Experimental de Inmunoterapia   (Venezuela)

Author keywords

Autologous; BCG; Breast cancer; Immunotherapy; Vaccine

Indexed keywords

BCG VACCINE; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIFE EXPECTANCY; MOUSE; NONHUMAN; OVERALL SURVIVAL; SURVIVAL RATE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMORADIOTHERAPY; GUINEA PIG; HAMSTER; IMMUNOLOGY; MORTALITY; MYCOBACTERIUM BOVIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; CHEMORADIOTHERAPY; CRICETINAE; FEMALE; GUINEA PIGS; HUMANS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; SURVIVAL RATE;

EID: 84944511690     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1320-0     Document Type: Article

References (24)

1. Liu Y, Hou G, Zhang X, Liu JJ, Zhang S, Zhang J. A pilot randomized clinical study of the additive treatment effect of photodynamic therapy in breast cancer patients with chest wall recurrence. J Breast Cancer. 2014;17(2):161–6.
2. Lee MC, Jagsi R. Postmastectomy radiation therapy: indications and controversies. Surg Clin North Am. 2007;87(2):511–26.
3. May M, Brookman-May S, Hoschke B, Gilfrich C, Kendel F, Baxmann S, et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother. 2010;59(5):687–95.
4. Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A, et al. Breast cancer and the immune system. J Soc Integr Oncol. 2008;6(4):158–68.
5. Reisfeld RA. The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog. 2013;18(1–2):115–33.
6. Hayes DF, Paoletti C. Circulating tumour cells: insights into tumour heterogeneity. J Intern Med. 2013;274(2):137–43.
7. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–54.
8. Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccines Immunother. 2014;10(1):52–63.
9. Dols A, Meijer SL, Smith JW 2nd, Fox BA, Urba WJ. Allogeneic breast cancer cell vaccines. Clin Breast Cancer. 2003;3(4):S173–80.
10. Jocham D, Richter A, HoVmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal cell carcinoma after radical nephrectomy phase III randomized controlled trial. Lancet. 2004;363(9409):594–9.
11. Han RF, Pan JG. Can intravesical bacillus Calmette–Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–23.
12. Cáceres-Dittmar G, Tapia FJ, Sanchez MA, Yamamura M, Uyemura K, Modlin RL, et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol. 1993;91(3):500–5.
13. Gross A, Weiss E, Tapia FJ, Aranzazu N, Gallinoto ME, Convit J. Leukocyte subsets in the granulomatous response produced after inoculation with Mycobacterium leprae-BCG in lepromatous patients. Am J Trop Med Hyg. 1988;38(3):608–12.
14. Convit J, Pinardi ME, Rodríguez Ochoa G, Ulrich M, Avila JL, Goihman M. Elimination of Mycobacterium leprae subsequent to local in vivo activation of macrophages in lepromatous leprosy by other mycobacteria. Clin Exp Immunol. 1974;17(2):261–5.
15. Convit J, Aranzazu N, Pinardi ME, Ulrich M. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG. Clin Exp Immunol. 1979;36(2):214–20.
16. Convit J, Ulrich M, Aranzazu N, Castellanos PL, Pinardi ME, Reyes O. The development of a vaccination model using two microorganisms and its application in leprosy and leishmaniasis. Lepr Rev. 1986;57(2):263–73.
17. Convit J, Ulrich M. Desarrollo de una autovacuna + BCG y su posible uso en el tratamiento del cáncer. Gac Méd. 2006;114(4):300–4.
18. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
19. Schirrmacher V, Fournier P, Schlag P. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines. 2014;13(1):117–30.
20. Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunotherapy. Science. 2013;342(6165):1432–3.
21. Keenan BP, Jaffee EM. Whole cell vaccines-past progress and future strategies. Semin Oncol. 2012;39(3):276–86.
22. Wiseman CL. Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Investig. 1995;13(3):267–71.
23. Holmberg LA, Sandmaier B. Vaccination as a treatment for breast or ovarian cancer. Expert Rev Vaccines. 2004;3(3):269–77.
24. Hanna MG Jr. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Hum Vaccines Immunother. 2012;8(8):1156–60.